Abstract

SO.11.03

Bevacizumab by pterygium recurrence

Swetlana Leippi, Franz Grehn, Gerd Geerling
Universitäts-Augenklinik Würzburg

Objective
A pterygium is defined as a fibro-vascular and hyperplastic proliferative degeneration tissue at the limbus. Although the pathogenesis is not yet clearly understood, there are multiple references that VEGF may play a significant role in the development of pterygia. In spite of various surgical approaches recurrence remains the major postoperative problem. Bevacizumab is a human monoclonal antibody against vascular endothelial growth factor (VEGF). Its antiangiogenic effect is used in ophthalmology as an off-label treatment for retinal disease. We report about the use of Bevacizumab eye drops to prevent repeated recurrence of pterygia.
Methods
We treated 7 eyes (6 patients) with topical Bevacizumab eye drops or subconjunctival injection as an adjunct after excision of recurrent pterygium and conjunctival autograft. Patients were examined preoperatively and over a follow-up of 14-22 months (median 20 months).
Results
Visual acuity improved in 4 of 7 eyes. In 6 eyes a prominent regression of neovascularization without pterygium recurrence was noted. In only one eye an early recurrence with corneal vascularisation and superficial punctate keratopathy was observed (stage 3 recurrence). No ocular or systemic adverse events were observed.
Conclusions
Considering the multiple recurrences in our patients we think that these first clinical medium follow-up experiences support the use of VEGF-inhibitors in recurrent pterygia.

Copyright: 2009 Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.